Immediate Impact
4 from Science/Nature 56 standout
Citing Papers
Targeting the tumour vasculature: from vessel destruction to promotion
2024 Standout
Evaluating eligibility criteria of oncology trials using real-world data and AI
2021 StandoutNature
Works of Sidney Scudder being referenced
Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
2007
Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment
2001
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Sidney Scudder | 564 | 592 | 400 | 49 | 1.9k | |
| Paul Smith | 391 | 1148 | 530 | 61 | 2.5k | |
| R. Otter | 381 | 1184 | 189 | 58 | 2.6k | |
| Paul R. Harnett | 365 | 843 | 542 | 98 | 2.1k | |
| Magdalena Bielska‐Lasota | 225 | 1400 | 264 | 27 | 2.5k | |
| Ashley Stuckey | 235 | 621 | 239 | 82 | 1.8k | |
| J. Renard | 874 | 654 | 345 | 56 | 1.9k | |
| Maurie Markman | 317 | 466 | 282 | 86 | 1.5k | |
| Nachimuthu Natarajan | 288 | 743 | 521 | 58 | 2.6k | |
| George B. Hutchison | 280 | 477 | 139 | 35 | 1.9k | |
| A. De Matteis | 234 | 1181 | 314 | 56 | 2.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...